Research Article| Volume 102, ISSUE 4, P243-245, October 2020

Reduction in use of cyproterone/ethinylestradiol (Diane-35 and generics) after risk minimization measures in the Netherlands, UK and Italy



      To study the effect of risk minimization measures taken in 2013 for cyproterone acetate/ethinylestradiol (CPA/EE) on initiation, concomitant use of other hormonal contraceptives (HC) and potential indications.

      Study design

      This retrospective study included data on CPA/EE use in 2011–2017 from the Netherlands, UK, and Italy.


      The initiation rate of CPA/EE decreased by 44%–91% between 2011 and 2017. Proportions with concomitant use of other HC (<3%) and approved indications did not change over time.


      Apart from a strong reduction in CPA/EE use following risk minimization measures, no major changes were observed regarding concomitant use of other HC or potential reasons for use.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lidegaard O.
        • Lokkegaard E.
        • Svendsen A.L.
        • Agger C.
        Hormonal contraception and risk of venous thromboembolism: national follow-up study.
        BMJ. 2009; 339b2890
        • Lidegaard O.
        • Nielsen L.H.
        • Skovlund C.W.
        • Skjeldestad F.E.
        • Lokkegaard E.
        Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9.
        BMJ. 2011; 343d6423
        • Vasilakis-Scaramozza C.
        • Jick H.
        Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives.
        Lancet. 2001; 358: 1427-1429
      1. European Medicines Agency. Assessment report cyproterone acetate/ethinylestradiol (2 mg/0.035 mg) containing medicinal products. 2013.

      2. EU PAS Register Number EUPAS8412 - Drug Utilization Study on Diane®-35 (and generics) in European healthcare databases. In: European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP).

        • Cea Soriano L.
        • Asiimwe A.
        • Garcia Rodriguez L.A.
        Prescribing of cyproterone acetate/ethinylestradiol in UK general practice: a retrospective descriptive study using The Health Improvement Network.
        Contraception. 2017; 95: 299-305
        • Lapi F.
        • Simonetti M.
        • Cricelli I.
        • Cricelli C.
        • Cassano N.
        • Vena G.A.
        Prescription appropriateness of cyproterone acetate/ethinylestradiol in primary care: a population-based study in Italy.
        Clin Drug Investig. 2017; 37: 755-762
        • Bezemer I.D.
        • Smits E.
        • Penning-van Beest F.J.A.
        • Asiimwe A.
        • Herings R.M.C.
        Thrombotic risk minimization for Diane-35 and generics.
        Pharmacoepidemiol Drug Saf. 2017; 26: 1411-1417